Research Topics
Genomes and Genes
Species | Daniel CatovskySummaryAffiliation: Institute of Cancer Research Country: UK Publications
| Collaborators
|
Detail Information
Publications
Familial multiple myelomaDaniel Catovsky
Institute of Cancer Research, Sutton, Surrey, UK
Haematologica 90:3-4. 2005
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialD Catovsky
Section of Haemato oncology, Institute of Cancer Research, Sutton, UK
Lancet 370:230-9. 2007..We aimed to establish whether this treatment combination provided greater survival benefit than did chlorambucil or fludarabine...
Chlorambucil--still not bad: a reappraisalDaniel Catovsky
Section of Haemato oncology, The Institute of Cancer Research, Sutton, United Kingdom
Clin Lymphoma Myeloma Leuk 11:S2-6. 2011..It remains a useful drug for patients unfit to receive more intensive combinations. However, both the dose and duration of treatment are important...
Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia riskDalemari Crowther-Swanepoel
Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
Br J Haematol 150:473-9. 2010..CLL risk increased with increasing numbers of risk alleles (P(trend) = 1.40 x 10(-15)), consistent with a polygenic model of disease susceptibility. These data validate the relationship between common variation and risk of CLL...
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trialDavid Gonzalez
Section of Haemato oncology, The Institute of Cancer Research, London, United Kingdom
J Clin Oncol 29:2223-9. 2011..We aimed to address the frequency and prognostic value of TP53 abnormalities in patients with CLL in the context of a prospective randomized trial...
Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locusDalemari Crowther-Swanepoel
Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
Hum Mol Genet 19:1840-5. 2010..These four SNPs map to a 3 kb region of the 3'-UTR of IRF4, consistent with the causal basis of the association being mediated through differential IRF4 expression...
Genetic variation in CXCR4 and risk of chronic lymphocytic leukemiaDalemari Crowther-Swanepoel
Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Road, Sutton, United Kingdom
Blood 114:4843-6. 2009..Our analysis provides no evidence that common variation in CXCR4 defined by rs228014 influences the risk of CLL, but that functional coding mutations in CXCR4 may contribute to familial CLL...
The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemiaClaire Dearden
Royal Marsden National Health Service NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK
Blood 111:1820-6. 2008..In conclusion, DAT status at the time of initiation of therapy provides a new prognostic indicator, although FC may protect against AHA. This trial was registered at http://isrctn.org as no. 58585610...
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemiaMonica Else
Section of Haemato oncology, Royal Marsden Hospital Institute of Cancer Research, Sutton, United Kingdom
Cancer 110:2240-7. 2007..They continue to be effective at second- and even third-line therapy; however, alternative treatments are needed for patients who are or have become refractory to these agents or whose remissions are shorter with each course of therapy...
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosisMonica Else
The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, UK
Br J Haematol 145:733-40. 2009..Overall only eight patients died of HCL-related causes. Patients achieving a CR can expect a normal lifespan...
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrenceMonica Else
The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, UK
Leuk Lymphoma 52:75-8. 2011..006). The combination of a purine analog with rituximab was safe and effective for patients with recurrent HCL. The results suggest an added benefit compared with single-agent purine analog therapy...
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemiaMaria Chiara Di Bernardo
Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
Nat Genet 40:1204-10. 2008..32 (rs11083846, PRKD2; P = 3.96 x 10(-9)). These data provide the first evidence for the existence of common, low-penetrance susceptibility to a hematological malignancy and new insights into disease causation in CLL...
Lack of a relationship between the common 18q24 variant rs12953717 and risk of chronic lymphocytic leukemiaPeter Broderick
Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
Leuk Lymphoma 49:271-2. 2008..99 (95% CI: 0.85 - 1.16) and 0.91 (95% CI: 0.74 - 1.11) for heterozygotes and TT homozygotes, respectively. These data suggests variation at SMAD7 does not significantly contribute to an inherited susceptibility to CLL...
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia riskDalemari Crowther-Swanepoel
Institute of Cancer Research, Sutton, Surrey, UK
Nat Genet 42:132-6. 2010..2 (rs783540, CPEB1; OR = 1.18; P = 3.67 x 10(-6)) and 18q21.1 (rs1036935; OR = 1.22; P = 2.28 x 10(-6)). These data provide further evidence for genetic susceptibility to this B-cell hematological malignancy...
T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literatureNnenna Osuji
Section of Haemato oncology, Institute of Cancer Research, London, United Kingdom
Cancer 107:570-8. 2006..To the authors' knowledge, there is no standard treatment for patients with T-cell large granular lymphocyte (LGL) leukemia. Available data are limited by patient numbers and coexisting pathologies...
Inherited genetic susceptibility to monoclonal B-cell lymphocytosisDalemari Crowther-Swanepoel
Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
Blood 116:5957-60. 2010..27; P = 7.75 × 10(-3)), rs2456449 (OR = 1.31; P = 3.14 × 10(-3)), and rs735665 (OR = 1.63; P = 6.86 × 10(-6)). Collectively, these data provide support for genetic variation influencing CLL risk through predisposition to MBL...
Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLLAlison Morilla
Section of Haemato oncology, The Institute of Cancer Research, Sutton, Surrey, UK
Leuk Lymphoma 49:2108-15. 2008..Simultaneous analysis of ZAP-70, CD38 and IGHV mutations in CLL provides more discriminatory prediction of TFI than any factor alone...
Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia riskDalemari Crowther-Swanepoel
Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
Br J Haematol 154:229-33. 2011..These data provide further evidence for the involvement of common genetic variants in CLL risk and insight into the biological basis of disease development...
Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trialMonica Else
Section of Haemato oncology, The Institute of Cancer Research, Sutton, Surrey, UK
Br J Haematol 143:690-7. 2008..001*). These findings support the recommendation to begin treatment when patients experience symptomatic disease, to improve HRQoL...
Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosisGabrielle S Sellick
Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
Blood 111:1625-33. 2008..To facilitate the identification of prognostic markers through pooled analyses, we have made all data from our analysis publicly available...
Long-term results for pentostatin and cladribine treatment of hairy cell leukemiaClaire E Dearden
Department of Haemato Oncology, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
Leuk Lymphoma 52:21-4. 2011..Overall, only eight patients have died of HCL-related causes. Patients with HCL who achieve a CR can expect a normal lifespan...
Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous routeClaire E Dearden
The Royal Marsden National Health Service NHS Trust, Sutton, United Kingdom
Blood 118:5799-802. 2011..Alemtuzumab delivered intravenously, but not subcutaneously, remains the treatment of choice for previously untreated T-PLL. This study is registered at www.eudract.ema.europa.eu as #2004-004636-31...
Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLLDalemari Crowther-Swanepoel
Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom
Blood 111:5691-3. 2008..These observations provide evidence that familial CLL is essentially indistinguishable from sporadic CLL, favoring a genetic basis to disease development in general rather than a simple environmental etiology...
Relationship between ARLTS1 polymorphisms and risk of chronic lymphocytic leukemiaGabrielle S Sellick
Section of Cancer Genetics, Brooks Lawley Building, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
Leuk Res 30:1573-6. 2006..None of the SNPs were individually significantly associated with risk of CLL and there was no evidence for epistatic interaction between loci. Our study does not support the postulate that variants of ARLTS1 influence the risk of CLL...
Histopathology of the spleen in T-cell large granular lymphocyte leukemia and T-cell prolymphocytic leukemia: a comparative reviewNnenna Osuji
Section of Haemato oncology, Royal Marsden Hospital Foundation Trust Institute of Cancer Research, London UK
Am J Surg Pathol 29:935-41. 2005....
Causation of chronic lymphocytic leukemia--insights from familial diseaseRichard S Houlston
Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
Leuk Res 27:871-6. 2003..Here, we review the current status of knowledge about inherited susceptibility to CLL...
Differential diagnosis in chronic lymphocytic leukaemiaEstella Matutes
Haemato oncology Department, The Royal Marsden Hospital and Institute of Cancer Research, 203 Fulham Road, London SW3 6JJ, UK
Best Pract Res Clin Haematol 20:367-84. 2007..Fluorescence in-situ hybridization (FISH) analysis also provides prognostic information, chiefly by detecting 17 (p53 locus) and 11q deletion, and may determine the type of therapy...
Diagnostic issues in chronic lymphocytic leukaemia (CLL)Estella Matutes
Section of Haemato Oncology Department, The Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK
Best Pract Res Clin Haematol 23:3-20. 2010..In atypical CLL, histology and/or molecular genetics may be required to exclude other B-cell disorders...
Splenectomy in mantle cell lymphoma with leukaemia: a comparison with chronic lymphocytic leukaemiaRosa Ruchlemer
Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, London, UK
Br J Haematol 118:952-8. 2002..Differences seen between MCL and CLL in spleen size, and in response of the leucocytosis suggest a central role for the spleen in the evolution of MCL with leukaemia...
CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual diseaseMariano P Scolnik
Inmunología Oncológica, IIHEMA, Academia Nacional de Medicina de, Buenos Aires, Argentina
Leuk Res 26:615-9. 2002..Our results indicate that quantitative analysis of CD34 and CD117 may be useful to detect minimal residual disease (MRD) and could be tested in a future to monitor therapy in AML...
Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemiaVasantha Brito-Babapulle
FRC Path, Academic Department of Hematology and Cytogenetics, Royal Marsden NHS Trust Institute of Cancer Research, 203, Fulham Road, London SW3 6JJ, UK
Haematologica 87:357-62. 2002....
p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndromeV Brito-Babapulle
Department of Academic Haematology Cytogenetics, Royal Marsden Hospital NHS Trust and Institute of Cancer Research, London, UK
Br J Haematol 110:180-7. 2000..Alternatively, the frequent loss of the p53 gene could be associated with the deletion of an adjacent gene, which could be involved in the pathogenesis of these diseases...
Interleukin-6 and other gp130-dependent cytokines selectively inhibit proliferation of macrophage-lineage hemopoietic progenitor cellsR Clutterbuck
Academic Department of Haematology and Cytogenetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
Exp Hematol 28:1120-8. 2000..We have investigated the roles of interleukin-6 and other gp130-dependent ligands on the proliferation of macrophage-lineage hemopoietic progenitor cells...
The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patientsE Matutes
Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital NHS Trust, Fulham Road, London SW3 6JJ, UK
Leuk Lymphoma 45:2007-15. 2004..Splenectomy is a useful treatment option in this group of patients...
Definition of acute biphenotypic leukemiaE Matutes
Academic Department of Hematology and Cytogenetics, Royal Marsden Hospital, London, UK
Haematologica 82:64-6. 1997..In this work we analyze diagnostic criteria for BAL...
Characteristic appearances of the bone marrow in T-cell large granular lymphocyte leukaemiaN Osuji
Section of Haemato oncology, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Sutton, Surrey, UK
Histopathology 50:547-54. 2007..To augment the limited literature on bone marrow (BM) appearances in T-cell large granular lymphocyte (LGL) leukaemia and to identify a histological signature to aid in diagnosis of this condition...
Deletions of D13S25, D13S319 and RB-1 mapping to 13q14.3 in T-cell prolymphocytic leukaemiaV Brito-Babapulle
Academic Department of Haematology and Cytogenetics Institute of Cancer Research, London, UK
Br J Haematol 114:327-32. 2001..Thus, 13q14.3 deletions could contribute to the development of overt leukaemia in T-PLL, but the involvement of more than one gene in the region cannot be excluded...
TCL1 is activated by chromosomal rearrangement or by hypomethylationM R Yuille
Academic Department of Haematology and Cytogenetics, Institute of Cancer Research, Sutton Surrey SM2 5NG, UK
Genes Chromosomes Cancer 30:336-41. 2001..We discuss the significance of this for CLL tumorigenesis and for genomewide hypomethylation in CLL...
The variant form of hairy-cell leukaemiaE Matutes
Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
Best Pract Res Clin Haematol 16:41-56. 2003..Transformation to large cell is seen in 6% of patients. The inferior survival in HCL-variant compared with typical HCL cases may reflect the chemotherapy resistance...
Transformation of T-cell large granular lymphocyte leukaemia into a high-grade large T-cell lymphomaE Matutes
Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital, NHS Trust, Fulham Road, London SW3 6JJ, UK
Br J Haematol 115:801-6. 2001..This is the first case documented by molecular methods of the transformation of the pre-existing clone...
Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesisP D Thornton
Section of Haemato-Oncology, Institute of Cancer Research, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
Leuk Res 29:389-95. 2005..We suggest that the relatively high incidence of transformation in this series may be due to immunosuppression mainly related to fludarabine, although other agents and prior therapies may have also contributed...
Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISHN Parry Jones
Section of Haemato oncology, Institute of Cancer Research and Royal Marsden NHS Trust, London and Surrey, UK
Br J Haematol 137:117-24. 2007..Deletion at 17p13 did not show prognostic impact in this series. CD38, positive in two-thirds of cases, was associated with male gender and nodal disease but not with any cytogenetic abnormality, or with survival...
Germline mutations in RAD51, RAD51AP1, RAD51B, RAD51C,RAD51D, RAD52 and RAD54L do not contribute to familial chronic lymphocytic leukemiaGabrielle Sellick
Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
Leuk Lymphoma 49:130-3. 2008..No overt pathogenic mutations were identified. These findings indicate that germline mutations in RAD51, RAD51AP1, RAD51L1, RAD51L3, RAD52 and RAD54L are unlikely to be causal of an inherited predisposition to CLL...
Familial chronic lymphocytic leukemiaGabrielle S Sellick
Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
Semin Oncol 33:195-201. 2006..Here we review the current status of knowledge relating to inherited susceptibility to CLL and the strategies that are being employed to identify disease-causing mutations...
A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemiaGabrielle S Sellick
Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK
Blood 110:3326-33. 2007..002). None of the regions coincided with areas of common chromosomal abnormalities frequently observed in CLL. These findings provide direct evidence for Mendelian predisposition to CLL and evidence for the location of disease loci...
Molecular cloning of complex chromosomal translocation t(8;14;12)(q24.1;q32.3;q24.1) in a Burkitt lymphoma cell line defines a new gene (BCL7A) with homology to caldesmonV J Zani
Academic Department of Haematology and Cytogenetics, Institute of Cancer Research Royal Marsden Hospital, Sutton, Surrey, UK
Blood 87:3124-34. 1996..Disruption of the amino-terminus of BCL7A defines a new mechanism in the pathogenesis of a subset of high-grade B-NHL...
Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 yearsMonica Else
Section of Haemato-Oncology, Royal Marsden NHS Foundation Trust/Institute of Cancer Research (ICR, Sutton, United Kingdom
Cancer 104:2442-8. 2005..True cure in HCL remains elusive, but the addition of monoclonal antibodies may be beneficial. Our results suggest that achieving CR should remain the main goal of treatment...
Familial chronic lymphocytic leukemiaRichard S Houlston
Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
Curr Hematol Malig Rep 3:221-5. 2008..This article reviews current knowledge relating to inherited susceptibility to CLL and strategies that are being used to identify disease-causing mutations...
Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisationHannah C Rudenko
Section of Haemato oncology, The Institute of Cancer Research ICR, Sutton, Surrey, London, UK
Leuk Lymphoma 49:1879-86. 2008..02). In particular, amplification of 2p and deletion of 6q were both more frequent. Cases with >20%TP53-deleted cells had the worst prognosis in the LRF CLL4 trial...
Incidence of MLL rearrangement in acute myeloid leukemia, and a CALM-AF10 fusion in M4 type acute myeloblastic leukemiaSaid M H Abdou
Academic Department of Haematology and Cytogenetics, The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK
Leuk Lymphoma 43:89-95. 2002..Our data confirm the value of combining cytogenetic, FISH and molecular analyses to define the incidence and precise nature of MLL and 11q23 abnormalities in AML...
ATM mutations are rare in familial chronic lymphocytic leukemiaMartin R Yuille
Academic Department of Haematology and Cytogenetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
Blood 100:603-9. 2002..Common ATM missense mutations were not overrepresented. The data support previous observations that ATM mutation is associated with B-CLL. However, ATM mutations do not account for familial clustering of the disease...
Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemiaIlaria del Giudice
Section of Hemato-Oncology, Institute of Cancer Research, Sutton, Surrey, United Kingdom
Cancer 104:2124-32. 2005..00001). CONCLUSIONS: The current findings suggested that both ZAP-70 and CD38 should be tested prospectively in all patients with early-stage CLL...
IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL)I Del Giudice
Section of Haemato Oncology Institute of Cancer Research, Sutton, UK
Leukemia 20:1231-7. 2006..B-PLL appears biologically heterogeneous regarding IgVH mutations, ZAP-70 and CD38 expression, showing a pattern distinct from that of other lymphoproliferative disorders...
Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*Gail Jones
Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Br J Haematol 156:186-95. 2012..This revision updates those guidelines and covers the areas of diagnosis, treatment and assessment of response to therapy...
Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemiaMatthew F Rudd
Sections of Cancer Genetics and Haemato Oncology, Institute of Cancer Research, Sutton, Surrey, UK
Blood 108:638-44. 2006..68, P = .0006), CHEK2 I157T (OR = 14.83, P = .0008), BRCA2 N372H (OR = 1.45, P = .0032), and BUB1B Q349R (OR = 1.42, P = .0038). Our findings implicate variants in the ATM-BRCA2-CHEK2 DNA damage-response axis with risk of CLL...
Breakpoints in the ataxia telangiectasia gene arise at the RGYW somatic hypermutation motifPaul S Bradshaw
Academic Department of Haematology and Cytogenetics, Institute of Cancer Research, Sutton, Surrey, UK
Oncogene 21:483-7. 2002..The structures of the ATM duplications suggest they may arise from an error in somatic hypermutation. We suggest that aberrant components of somatic hypermutation may contribute to the defective DSB repair characteristic of cancer...
Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?I Chau
Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
Br J Cancer 89:36-42. 2003..Anthracyclines did not appear to influence survival or disease relapses when given as front-line therapy in our series. The role of anthracyclines should be further evaluated in large randomised studies...
An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphomaI Chau
Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
Br J Haematol 115:786-92. 2001..It has clinically significant activity with an acceptable toxicity profile. Lack of renal toxicity makes DHAX an attractive cytoreductive regimen before high-dose chemotherapy...
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphomaM Ng
Department of Medicine, Royal Marsden Hospital, Surrey, UK
Br J Cancer 92:1352-7. 2005..Grade 3 or 4 nonhaematological toxicity was minimal and stem cell mobilisation was not inhibited. GEM-P is an effective salvage regimen and its use prior to autologous stem cell transplant warrants further investigation...
Characterization of a t(10;11)(p13-14;q14-21) in the monoblastic cell line U937J Shipley
Institute of Cancer Research, Sutton, Surrey, United Kingdom
Genes Chromosomes Cancer 13:138-42. 1995..Further characterization of the genetic rearrangements in U937 may lead to the isolation of genes important in leukemogenesis and provide an in vitro system for their study...
A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility lociGabrielle S Sellick
Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom
Am J Hum Genet 77:420-9. 2005..01). None of the regions coincided with areas of common chromosomal abnormalities frequently observed for CLL. These findings strengthen the argument for an inherited predisposition to CLL and related B-cell LPDs...
The P2X7 receptor gene A1513C polymorphism does not contribute to risk of familial or sporadic chronic lymphocytic leukemiaGabrielle S Sellick
Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey
Cancer Epidemiol Biomarkers Prev 13:1065-7. 2004..80-1.31). A meta-analysis of this study and five other smaller published studies provides no evidence of relationship between this P2X7 polymorphism and risk of CLL (odds ratio = 0.99, 95% confidence interval: 0.74-1.32)...
MTHFR polymorphisms and risk of chronic lymphocytic leukemiaMatthew F Rudd
Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom
Cancer Epidemiol Biomarkers Prev 13:2268-70. 2004..97 (95% CI, 0.79-1.18) and 0.88 (95% CI, 0.62-1.24), respectively. This data indicate that the MTHFR polymorphisms C677T and A1298C do not significantly contribute to an inherited genetic susceptibility to CLL...
Chromosomal imbalances in familial chronic lymphocytic leukaemia: a comparative genomic hybridisation analysisB Summersgill
UK Co-ordinating Centre for the Study of Familial Chronic Lymphocytic Leukaemia, Section of Molecular Carcinogenesis, Institute of Cancer Research, Sutton, UK
Leukemia 16:1229-32. 2002..This suggests these regions may harbour a susceptibility locus for CLL. There is also some evidence that chromosome regions 2p12-p14 and 4q11-q21 may harbour predisposition genes...
EPIC: an effective low toxicity regimen for relapsing lymphomaT Hickish
Lymphoma Unit, Royal Marsden Hospital, Sutton, Surrey, London, UK
Br J Cancer 68:599-604. 1993..The EPIC regimen has equivalent activity to other reported cisplatin based regimens used in the treatment of recurrent lymphoma, but is associated with lower treatment related morbidity and mortality...
Microsatellite instability indicative of defects in the major mismatch repair genes is rare in patients with B-cell chronic lymphocytic leukemia: Evaluation with disease stage and family historyG S Sellick
Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
Leuk Lymphoma 48:1320-2. 2007..In conclusion, our study demonstrates that MSI does not have a prominent role in the pathogenesis of B-CLL...
Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21T G Willis
Academic Department of Haematology and Cytogenetics, Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, UK
Blood 91:1873-81. 1998..These data suggest that BCL9 may be the target of translocation in some B-cell malignancies with abnormalities of 1q21 and that deregulated BCL9 expression may be important in their pathogenesis...
The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytesIlaria del Giudice
Academic Department of Hematology and Cytogenetics, The Royal Marsden Hospital and Institute of Cancer Research, London, UK
Haematologica 89:303-8. 2004..However CD123 does not allow the distinction between HCL-variant and SLVL, as both are CD123 negative...
High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapyMoez Dungarwalla
Haematologica 93:475-6. 2008..Despite its efficacy the combination is not easily manageable because of the high rate of opportunistic infections...
High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalitiesPatrick D Thornton
Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, London, UK
Ann Hematol 82:759-65. 2003..This study demonstrates that HDMP alone or in combination with other agents is a useful treatment strategy in refractory CLL including patients with p53 abnormalities...
Granulomatous slack skin disease--disease features and response to pentostatinNnenna Osuji
Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital, London, UK
Br J Haematol 123:297-304. 2003..The patient has twice achieved a good response to pentostatin after failure of combination chemotherapy. This is the first report of the successful use of the purine analogue pentostatin in the management of GSSD...
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphomaIan Chau
Department of Medicine, Royal Marsden Hospital, London, UK
Br J Haematol 120:970-7. 2003..9-80.5%). In conclusion, GEM-P is a novel combination salvage therapy for poor-prognostic primary progressive or multiply relapsed lymphoma patients. It has clinically significant activity with a favourable toxicity profile...
Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patientsNilima Parry-Jones
Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, London, UK
Br J Haematol 120:759-64. 2003..001 for SLVL deaths). We conclude that SLVL is mainly a disease of the elderly with a relatively benign course but, when treatment is required, splenectomy is beneficial...
A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal diseaseJenny Orchard
Department of Haematology, Royal Bournemouth Hospital, United Kingdom
Blood 101:4975-81. 2003..We find no evidence against a diagnosis of MCL in the nonnodal group and suggest that mutated IgVH genes may help identify patients with indolent disease...
Delineation of the minimal region of loss at 13q14 in multiple myelomaManal O Elnenaei
Department of Academic Haematology and Cytogenetics, The Institute of Cancer Research and Royal Marsden NHS Trust, London, United Kingdom
Genes Chromosomes Cancer 36:99-106. 2003..However, a role for RFP2 in the pathogenesis of MM cannot yet be excluded, given that alternative mechanisms such as haploinsufficiency remain possible...
Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutationsAnne Tierens
Departments of Pathology and Tumor Biology, The Norwegian Cancer Institute and Radiumhospital, University of Oslo, Oslo, Norway
Am J Pathol 162:681-9. 2003..Our results indicate that marginal zone lymphomas at different anatomical localizations may derive from a similar B-cell subset...
CD38 expression as a prognostic indicator in chronic lymphocytic leukaemiaPatrick D Thornton
1Academic Department of Haematology and Cytogenetics, Institute of Cancer Research and Royal Marsden NHS Trust, London, UK
Hematol J 5:145-51. 2004..We conclude that 7% may be a more useful threshold for disease progression than higher values of CD38...
B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemiaRosa Ruchlemer
Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital and Institute of Cancer Research, London, UK
Br J Haematol 125:330-6. 2004..These cases illustrate the importance of tissue diagnosis with cyclin D1 staining and fluorescence in situ hybridization analysis in B-cell leukaemia with prolymphocytic features...
Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy aloneApostolia M Tsimberidou
Department of Leukemia, Unit 428, The University of Texas M D Anderson Cancer Center, Houston, Texas77030, USA
Cancer 107:125-35. 2006..The objective of this retrospective study was to compare the outcomes of patients with SMZL who received treatment with rituximab, rituximab plus chemotherapy, or chemotherapy alone...
The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven casesYang O Huh
Department of Hematopathology, MD Anderson Cancer Centre, The University of Texas, Houston, TX 77030, USA
Br J Haematol 136:220-8. 2007..However, these neoplasms also differ from CLL cytologically and in their immunophenotype...
Lessons from a case of T-cell large granular lymphocytic leukaemia suggesting that immunomodulatory therapy is more effective than intensive treatmentNnenna Osuji
Section of Haemato-Oncology, Department of Histopathology, Institute of Cancer Research, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, United Kingdom
Leuk Res 29:225-8. 2005..We highlight the resistant nature of the LGL clone and discuss the relative merits of immunomodulatory type therapy in this disease...
Molecular cytogenetic study of a mantle cell lymphoma with a complex translocation involving the CCND1 (11q13) regionSonia Maravelaki
Academic Department of Haematology and Cytogenetics, Institute of Cancer Research/Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
Cancer Genet Cytogenet 154:67-71. 2004..This case further illustrates the value of M-FISH in combination with fusion probes in elucidating complex cytogenetic abnormalities...
Isolated bone marrow involvement in diffuse large B cell lymphoma: a report of three cases with review of morphological, immunophenotypic and cytogenetic findingsCaroline L Alvares
Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital, London SW3 6JJ, UK
Leuk Lymphoma 45:769-75. 2004..These cases serve to highlight the biological and cytogenetic heterogenity of DLBL and emphasize the need for complementary investigations in the characterization of this entity...
Definition and diagnosis of sporadic and familial chronic lymphocytic leukemiaDaniel Catovsky
Academic Department of Haematology, The Institute of Cancer Research and Royal Marsden Hospital, 203 Fulham Road, London SW3 6JJ, UK
Hematol Oncol Clin North Am 18:783-94, vii. 2004..No candidate gene has been linked to the high incidence of CLL (10%) seen in families of patients with this disease...
Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomasLynda Song
Department of Medicine, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, Illinois, USA
Cancer Res 65:4554-61. 2005..Assessment of cDNA array profiles should further help us to design a working model for SMRT involvement in non-Hodgkin lymphoma transformation as a novel, nonclassical tumor suppressor...
Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytesAlicja M Gruszka-Westwood
Academic Department of Haematology and Cytogenetics, Institute of Cancer Research/Royal Marsden NHS Trust, London, United Kingdom
Genes Chromosomes Cancer 36:57-69. 2003..The presence of a high incidence of abnormalities in the established hotspot areas and in particular the finding of biallelic deletions is indicative of the existence of genes important for the pathogenesis of SLVL in these areas...
p53 and mdm2 in mantle cell lymphoma in leukemic phaseMax Solenthaler
Central Hematology Laboratory, University Hospital, Inselspital, Bern, Switzerland
Haematologica 87:1141-50. 2002..This study aimed to assess the frequency, relationship and impact of p53 abnormalities and those of its inhibitor mdm2 in blastoid and non-blastoid MCL in leukemic phase...
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemiaJacques-Louis Binet
Rebecca and John Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0663, USA
Blood 107:859-61. 2006..Pending the outcome of such trials, treatment decisions outside the context of a clinical trial still should be based on guidelines established by the most recent National Cancer Institute-sponsored Working Group...
Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansionAndy C Rawstron
Academic Unit of Haematology and Oncology, University of Leeds, HMDS, West Yorkshire, Surrey, United Kingdom
Blood 100:2289-90. 2002..The detection of CLL-phenotype cells provides a surrogate marker of carrier status, potentially facilitating gene identification through mapping in families and direct analysis of isolated CLL-phenotype cells...
High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemiaDonald W Milligan
Department of Haematology, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK
Br J Haematol 133:173-5. 2006..4% (95% confidence interval, 2.5-24%). No analysed potential risk factor was predictive for MDS/AML development. We hypothesise that potential causative factors are fludarabine, low cell dose and transplant conditioning...
Unusual case of leukemic mantle cell lymphoma with amplified CCND1/IGH fusion geneAlicja M Gruszka-Westwood
Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, London, UK
Genes Chromosomes Cancer 33:206-12. 2002..This is to our knowledge the first description of amplification of the CCND1/IGH fusion gene in a human neoplasm, which may have played a role in the fulminating course of the disease in this patient...
Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responsesDonald W Milligan
Department of Haematology, Birmingham Heartlands Hospital, Birmingham, United Kingdom
Blood 105:397-404. 2005..Detectable molecular disease by PCR was highly predictive of disease recurrence. It is of concern that 5 of 65 (8%) patients developed posttransplant acute myeloid leukemia/myelodysplastic syndrome...
Recurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridizationClaus L Andersen
Department of Hematology, Laboratory of Cancer Cytogenetics, Arhus Sygehus, Tage Hansens Gade 2, DK-8000 Arhus C, Denmark
Cancer Genet Cytogenet 156:122-8. 2005..Our data suggest that SMZL constitute a genetically heterogeneous disease where gain of 3q25 and loss of 7q31 are the most likely imbalances to be involved in the pathogenesis of the disease...
Obituary. David Abraham Goitein GaltonBarbara Bain
Leuk Lymphoma 48:2277-8. 2007
Characterisation of TP53 abnormalities in chronic lymphocytic leukaemiaPatrick D Thornton
Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust and Institute of Cancer Research, London, UK
Hematol J 5:47-54. 2004..DNA sequencing adds little to these methods in identifying the population at risk...
Diagnostic significance of CD20 and FMC7 expression in B-cell disordersJulio Delgado
Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, Institute of Cancer Research, London, England
Am J Clin Pathol 120:754-9. 2003..FMC7 is of greater diagnostic value than CD20 for distinguishing CLL from other B-cell disorders; we recommend its continued use for this purpose...
The WHO classification of mature T-cell leukemiasDaniel Catovsky
Blood 104:2989-90; author reply 2990. 2004
CHEK2*1100delC and risk of chronic lymphocytic leukemiaGabrielle S Sellick
Leuk Lymphoma 47:2659-60. 2006
Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2AManal O Elnenaei
Academic Department of Haematology and Cytogenetics, The Institute of Cancer Research and Royal Marsden Hospital Trust, 203 Fulham Road, London SW3 6JJ, UK
Haematologica 88:529-37. 2003..The incidence of the latter two events was, however, higher than previously reported. Deletion of the TP53 gene predicted resistance to chemotherapy, highlighting its importance in this disease process...
Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemiaIlaria del Giudice
Haematologica 90:268-70. 2005..During follow-up post-treatment, seven delayed responses (54%) were observed, improving the initial overall response rate of 61% to a final response rate of 77%...
Pregnancy improves neutropenia in T-cell large granular lymphocyte leukaemiaNnenna Osuji
Section of Haemato-Oncology, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, Surrey SM2 5PT, UK
Br J Haematol 128:645-8. 2005..Pregnancy thus appears to have a beneficial effect on neutrophil count in T-cell LGL leukaemia...
